Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
when used in combination with other drugs these UGT inhibitors act to significantly enhance efficacy antiviral therapeutics that require UGT's for their systemic clearance. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2011 - 7 pages - $3,835
Jun 2008 - $2,500
Feb 2010 - 19 pages - $500
Feb 2012 - 1350 pages - $2,695
May 2011 - 15 pages - $250
May 2011 - 15 pages - $125
May 2011 - 102 pages - $3,835
Mar 2011 - 23 pages - $750
Oct 2009 - 30 pages - $995
Your selection
Browse By
- Therapeutic target
- Amenorrahea
- Androgen deficiency
- Endocrine system
- Estrogen replacement
- Growth disorders
- Hormonal disorder (other)
- Hormone replacement therapy
- Hurler's syndrome
- Hypogonadism
- Hypothalamic
- Menopause
- Pancreatic exocrine insufficiency
- Sex hormone (other)
- Testosterone replacement
- Thyroid disorders
- Turner's syndrome
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us